Tratamiento con trióxido de arsénico en paciente con recaída de leucemia promielocítica aguda

Arsenic Trioxide: Pharmacological Applications

“…Among these mechanisms is the degradation of the fusion protein product of the PML/RARA gene, which causes the blocking of genes responsible for myeloid differentiation. On the other hand, ATO at lower concentrations induces cell differentiation [4].…”

“…Acute myeloid leukemia (AML) is the most common in adults, with two incidence peaks, between 25 and 30 years old and 60 and 70 years old [4]. AML is caused by uncontrolled proliferation due to abnormal progenitor cells that accumulate in the bone marrow and blood.…”

“…Acute promyeloc y tic leukemia ( APL ) is a subtype of AML due to a translocation between chromosomes 15 and 17, which is t (15; 17) PML/ RARA. This rearrangement will allow a blockage in the differentiation of myeloid stem cells in the promyelocyte stage [4,7].…”

“…It can also be used for the consolidation phase, where it should be given once a day for five days, then a 2-day break, which is repeated for 4 to 5 weeks [10]. Some side effects that may arise after the use of this drug are dyspnea, fever of unknown origin, unexplained weight gain, hypotension, acute renal failure, the appearance of pulmonary and pericardial edema [12], headaches, fatigue, ar thralgia, myalgia, bone pain, itching, hyperkeratosis, skin hyperpigmentation, exfoliative dermatitis, inflammation of the mucous membranes of the eyes, nose, mouth and digestive tract, abdominal cramps, diarrhea, hypokalaemia, hypomagnesemia, elevated transaminases, segment prolongation QT on the electrocardiogram and sudden deaths [1].…”